Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of optimally effective therapies. The combination of daclatasvir (DCV; pangenotypic nonstructural protein 5A inhibitor) and sofosbuvir (SOF; nucleotid...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroy, Vincent, Angus, Peter, Bronowicki, Jean‐Pierre, Dore, Gregory J., Hezode, Christophe, Pianko, Stephen, Pol, Stanislas, Stuart, Katherine, Tse, Edmund, McPhee, Fiona, Bhore, Rafia, Jimenez‐Exposito, Maria Jesus, Thompson, Alexander J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069621/
https://www.ncbi.nlm.nih.gov/pubmed/26822022
http://dx.doi.org/10.1002/hep.28473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069621/
https://www.ncbi.nlm.nih.gov/pubmed/26822022
http://dx.doi.org/10.1002/hep.28473

Ejemplares similares